US2004043013A1PendingUtilityA1

Metabolic uncoupling therapy

Priority: Dec 28, 2000Filed: Jun 17, 2003Published: Mar 4, 2004
Est. expiryDec 28, 2020(expired)· nominal 20-yr term from priority
Inventors:Edward Mccleary
A61K 31/385A61K 36/328A61K 31/4415A61K 45/06A61K 31/714A61K 31/455A61K 31/4188A61K 38/38A61K 31/205A61K 31/122A61K 31/7076A61P 17/00A61K 31/202A61K 33/06A61K 36/82A61K 31/201A61K 31/191A61K 33/24
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A combination of chemical agents reduces reductive stress by limiting the accumulation of high-energy electrons potentially available to the electron transport chain. A method of metabolic uncoupling therapy comprises: analyzing a specific physiologic process involving reductive stress; identifying a plurality of MUT agents that modulate metabolic pathways by influencing electron flux; and formulating a combination of MUT agents that limits the accumulation of high-energy electrons potentially available to the electron transport chain.

Claims

exact text as granted — not AI-modified
1 . A composition of agents for metabolic uncoupling therapy, comprising: 
 two or more Group 1 agents;    one or more Group 4 agents;    two or more Group 5 agents; and    one or more Group 6 agents;    wherein Group 1 agents are selected from a group consisting of TMG (Trimethylglycine), choline, phosphatidyl choline, SAMe (S-adenosyl methionine), carnitine, ALC (acetyl L-carnitine), propionyl carnitine, (myo)inositol, sphingomyelin, glycerylphosphorylcholine, and acetylcholine;    Group 4 agents are selected from a group consisting of PYR (Pyruvate), ASP (Aspartate), GLY (Glycine), and SER(Serine);    Group 5 agents are selected from a group consisting of Folate, riboflavin, B1, B3, niacinamide, nicotinamide, polynicotinate, B6, B12, biotin, pantothenic acid, riboflavin, and related chemical species; and    Group 6 agents are selected from a group consisting of coenzyme Q10, lipoic acid, and acetoacetate:    
     
     
         2 . A composition as in  claim 1 , further comprising: 
 a Group 2 agent, selected from a group consisting of creatine and folic acid.    
     
     
         3 . A composition as in  claim 2  comprising creatine and TMG, wherein a weight ratio creatine/TMG has a value in a range of about from 1/20 to 30/1.  
     
     
         4 . A composition as in  claim 2  comprising creatine and carnitine, wherein a weight ratio creatine/carnitine has a value in a range of about from 1/10 to 250/1.  
     
     
         5 . A composition as in  claim 2  comprising creatine and pyruvate, wherein a weight ratio creatine/pyruvate has a value in a range of about from 1/20 to 25/1.  
     
     
         6 . A composition as in  claim 2  comprising creatine and aspartate, wherein a weight ratio creatine/aspartate has a value in a range of about from 1/10 to 25/1.  
     
     
         7 . A composition as in  claim 1 , further comprising: 
 a Group 3 agent, selected from a group consisting of DHA (Docosahexanoic acid), EPA (Eicosapentanoic acid), and albumin.    
     
     
         8 . A composition as in  claim 1 , further comprising: 
 a Group 7 agent, selected from a group consisting of polyphenolic agents and desferoximine.    
     
     
         9 . A composition as in  claim 1 , comprising: 
 coenzyme Q10, R alpha lipoic acid, TMG, phosphatidyl choline, SAMe, carnitine and aspartic acid.    
     
     
         10 . A composition as in  claim 1 , comprising: 
 creatine, R alpha lipoic acid, SAMe, EPA, TMG, pyruvate, phosphatidyl choline, and ALC.    
     
     
         11 . A composition as in  claim 1 , comprising: 
 aspartate, biotin, HCA, chromium, carnitine, choline, TMG, SAMe, ALA, folic acid, creatine, and niacinamide.    
     
     
         12 . A composition as in  claim 11 , further comprising MCT.  
     
     
         13 . A composition as in  claim 1 , comprising: 
 tocotrienols, aspartic acid, biotin, HCA, TMG, inositol, guggulipid, and folic acid.    
     
     
         14 . A composition as in  claim 13 , further comprising CLA.  
     
     
         15 . A composition as in  claim 1 , comprising: 
 coenzyme Q10, ALA, EPA, chromium, aspartate, biotin, folate, L-arginine and creatine.    
     
     
         16 . A composition as in  claim 1 , comprising: 
 phosphatidyl choline, choline, lysine, glutamine, ALA, niacin, folic acid, pyridoxal phosphate, SAMe, ALC, CLA, and EPA.    
     
     
         17 . A composition as in  claim 1 , comprising: 
 glycerylphosphorylcholine, creatine, ALC, ALA, niacinamide, coenzyme Q10, phosphatidyl choline, choline, and TMG.    
     
     
         18 . A composition as in  claim 1 , comprising: 
 sodium chloride, potassium, magnesium, glucose, ALA, ALC, Mg-creatine chelate, huperzine A, pyridoxal phosphate, folate and vitamin B12.    
     
     
         19 . A composition as in  claim 1 , comprising: 
 niacinamide, ALC, inositol, folic acid, choline, phosphatidylcholine, and ALA.    
     
     
         20 . A composition as in  claim 1 , comprising: 
 mannitol, Mg-creatine, ALC, phosphatidyl choline, glycerylphosphorylcholine, ALA, thiamin, pyridoxine, coenzyme Q10 and niacinamide.    
     
     
         21 . A composition as in  claim 1 , comprising: 
 ALA, coenzyme Q10, TMG, phosphatidyl choline, niacinamide, vitamin C and vitamin E.    
     
     
         22 . A composition as in  claim 1 , comprising: 
 ALA, coenzyme Q10, TMG, phosphatidyl choline, and CLA.    
     
     
         23 . A composition as in  claim 1 , comprising: 
 phosphatidylcholine, glycerylphosphorylcholine, pyruvate, serine, albumin, EPA, CLA, and ALC.    
     
     
         24 . A composition as in  claim 1 , comprising: 
 NaCl, ALA, green tea leaf extract, ALC, phosphatidylcholine, carnitine, L-arginine, magnesium citrate, choline, pyruvate, creatine and vitamin B12.    
     
     
         25 . A composition as in  claim 1 , comprising: 
 NaCl, pyruvate, carnitine, choline, inositol, TMG, ALA, phosphatidylcholine, BCAA, glutamine, ribose and vitamin B6.    
     
     
         26 . A composition as in  claim 1 , comprising: 
 creatine, taurine, BCAA, glutamine, ALC, carnitine, choline, sphyngomyelin, chromium, selenium, ALA, vanadyl sulfate, and arginine.    
     
     
         27 . A composition as in  claim 1 , comprising: 
 pyruvate, choline, TMG, ALC, NaHCO 3 , carnitine, pantothenate, vitamin B3, magnesium citrate, insulin, and antibiotic.    
     
     
         28 . A composition as in  claim 1 , comprising: 
 phosphatidyl choline, ALA, ALC, pyruvate, hydroxycitrate, biotin, chromium and carnitine.    
     
     
         29 . A composition as in  claim 28 , further comprising: magnesium creatine.  
     
     
         30 . A composition as in  claim 1 , comprising: 
 whey protein, niacin (B3), folate, creatine, carnitine, acetoacetate, ALA, phosphatidylcholine, ALC, inositol, TMG, biotin, and pyruvate.    
     
     
         31 . A composition as in  claim 1 , comprising: 
 potassium bicarbonate, serine, ALA, choline, carnitine, TMG, and ALC.    
     
     
         32 . A composition as in  claim 31  further comprising vitamin D and calcium.  
     
     
         33 . A composition as in  claim 1 , comprising three or more Group 1 agents.  
     
     
         34 . A composition as in  claim 33 , comprising three or more Group 5 agents.  
     
     
         35 . A composition as in  claim 1 , comprising four or more Group 1 agents.  
     
     
         36 . A composition as in  claim 35 , comprising three or more Group 5 agents.  
     
     
         37 . A method of metabolic uncoupling therapy comprising: 
 analyzing a specific physiologic process, including delineating the metabolic pathways related to reductive stress;    identifying a plurality of MUT agents that modulate said metabolic pathways by influencing electron flux; and    formulating a combination of MUT agents that limits the accumulation of high-energy electrons potentially available to the electron transport chain.    
     
     
         38 . A method of metabolic uncoupling therapy as in  claim 37  comprising: 
 including an MUT agent in said combination based on said agent's secondary properties.  
 
     
     
         39 . A method as in  claim 37 , further comprising: 
 selecting a plurality of MUT agents based on their synergistic interactions with each other.    
     
     
         40 . A method as in  claim 37 , further comprising: 
 combining specific amounts and ratios of said plurality of MUT agents in a MUT formulation for administration in a prescribed manner for a prescribed period of time.

Join the waitlist — get patent alerts

Track US2004043013A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.